<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427191</url>
  </required_header>
  <id_info>
    <org_study_id>AIPF004</org_study_id>
    <nct_id>NCT02427191</nct_id>
  </id_info>
  <brief_title>Micronized dHACM Injectable for the Treatment of Plantar Fasciitis</brief_title>
  <acronym>dHACM</acronym>
  <official_title>A Prospective, Single-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to the Saline Placebo Injection in the Treatment of Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as
      compared to the saline placebo injection in the treatment of plantar fasciitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 146 patients will be enrolled in this study. Each patient will receive 1
      injection and be evaluated for efficacy and safety during a 12-month observation period. The
      study is expected to be completed within 36 months, inclusive of enrollment and follow-up of
      all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% improvement over baseline Visual Analog Scale for Pain</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>20% improvement in Foot Function Index-Revised (FFI-R) score from baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample analysis for immuno-compatibility of first 20 patients in each treatment arm</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term FFI-R outcomes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term VAS Pain outcomes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term blood sample analysis for immuno-compatibility of first 20 patients in each treatment arm</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Fasciitis, Plantar</condition>
  <arm_group>
    <arm_group_label>AmnioFix® Injectable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AmnioFix® Injectable</intervention_name>
    <description>1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)</description>
    <arm_group_label>AmnioFix® Injectable</arm_group_label>
    <other_name>dHACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Injection</intervention_name>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Saline Injection</arm_group_label>
    <other_name>0.9% NaCl</other_name>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of plantar fasciitis for ≥ 1 month (30 days) and ≤ 18 months by
             the investigator

          2. VAS Pain scale of ≥ 45 mm at randomization

          3. Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any
             of the following modalities:

               -  RICE

               -  Stretching exercises

               -  NSAIDs

               -  Orthotics

          4. Diagnostic X-Ray within 6 months of enrollment showing view of calcaneus negative for
             calcaneal fracture or structural abnormalities

          5. BMI ≤ 40 kg/m2

          6. Age ≥ 21 years and &lt; 80

          7. Ability to sign Informed Consent and Release of Medical Information Forms

        Exclusion Criteria:

          1. Prior surgery or trauma to the affected site

          2. Subjects requiring bilateral plantar fasciitis treatment at time of enrollment

          3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in
             either limb within the last 3 months

          4. Has diabetes either Type I or Type II

          5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone
             attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.

          6. The presence of comorbidities that can be confused with or can exacerbate the
             condition- to be assessed by X-ray - including but not limited to:

               -  Calcaneal stress fracture

               -  Nerve entrapment syndrome (Baxter Nerve Syndrome)

               -  Fat pad atrophy

               -  Acute traumatic rupture of the plantar fascia

               -  Calcaneal tumor

               -  Tarsal tunnel syndrome

               -  Significant bone deformity of the foot that may interfere with the study

          7. Affected site exhibits clinical signs and symptoms of infection

          8. Known allergy or known sensitivity to Aminoglycosides, such as Gentamicin sulfate or
             Streptomycin sulfate

          9. Clinically significant abnormal laboratory tests at baseline, including CBC,
             PT/PTT/INR, liver function and creatinine, as determined by the investigator

         10. Patients who are non-ambulatory

         11. History of more than 14 days treatment with immuno-suppressants (including systemic
             corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who
             are anticipated to require such medications during the course of the study

         12. Prior radiation at the site

         13. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding
             enrollment

         14. Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired
             Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)

         15. History of any condition (including drug or alcohol abuse, medical or psychiatric
             condition) that is likely to impair understanding of or compliance with the study
             protocol, in the judgment of the investigator

         16. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women
             of childbearing potential who are planning to become pregnant during the time of the
             study OR are unwilling/unable to use acceptable methods of contraception (birth
             control pills, barriers, or abstinence)

         17. Workers' compensation patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Union Memorial Hospital, Baltimore, MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanley J Harris</last_name>
    <phone>770-651-9100</phone>
    <email>sharris@mimedx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donald Fetterolf, MD</last_name>
    <phone>770-651-9100</phone>
    <email>dfetterolf@mimedx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phyllis Houston</last_name>
      <phone>520-792-1450</phone>
      <phone_ext>4548</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Stegall</last_name>
      <phone>559-431-1700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayana Sarkisova</last_name>
      <phone>415-345-1195</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando VA Healthcare System</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. Veterans Administration Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Terry</last_name>
      <phone>708-202-4536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James A. Lovell Federal Health Care Center</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Dent</last_name>
      <phone>224-610-1307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timonium Foot and Ankle Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flossine Brown</last_name>
      <phone>410-554-4451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WJB Dorn VA Medical Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Cover</last_name>
      <phone>254-935-5717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Podiatry Group</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen McGee</last_name>
      <phone>757-523-0414</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic plantar fasciitis</keyword>
  <keyword>Heel pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

